Pharmatching.com Starts Google for Pharma and Biotech
The new Pharmatching.com launched its "Google for Pharma & Biotech." The platform is an easy-to-use-“Web2.0”-tool for finding the right partners in the pharmaceutical industry worldwide. It saves time and costs in all (out)sourcing and business development processes, as it fascilitates and accelerates the searching process for appropriate business partners significantly.
The new Pharmatching.com offers a portfolio of more than 5000 service providers covering the whole pharmaceutical value chain – from drug candidate discovery to block buster marketing. Buyers can collect them in their "sourcing cart" and send anonymous inquiries or place an anonymous request and receive applications from suitable providers. Providers can promote their services within extensive company profiles.
Besides, Pharmatching.com is the only source worldwide where providers of the life science industry can be rated. Upon these ratings weekly updated rankings of the industry´s highscorer & lowscorer are provided.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
